C4 Therapeutics, Inc. (CCCC)
|Net Income (ttm)||-52.11M|
|Trading Day||January 25|
|Day's Range||38.63 - 41.01|
|52-Week Range||22.80 - 41.01|
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies
– Phase 1/2 Clinical Study of CFT7455 Expected to Initiate in 1H 2021 – – Phase 1/2 Clinical Study of CFT7455 Expected to Initiate in 1H 2021 –
WATERTOWN, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively ...
An FDA nod on Isoray's prostate treatment using brachytherapy seeds sent ISR stock skyrocketing. There's risk with uncertain reward in this biopharma stock.
C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022
– Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC™ targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Under FDA Review; Initiation of Phase 1/2 T...
C4 Therapeutics, along with a host of others, is developing therapeutics in the cutting edge field of protein degraders. Blockbuster drugs like Revlimid and Pomalyst are now known to be protei...
WATERTOWN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively dest...
C4 Therapeutics, a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E a... [Read more...]
Biological Product (except Diagnostic) Manufacturing
|IPO Date |
Oct 2, 2020
|Stock Exchange |
|Ticker Symbol |
In 2019, CCCC's revenue was $21.38 million, an increase of 10.42% compared to the previous year's $19.36 million. Losses were -$34.10 million, 117.0% more than in 2018.
According to 3 analysts, the average rating for CCCC stock is "Strong Buy." The 12-month stock price forecast is 42.67, which is an increase of 5.70% from the latest price.